FTC Asks Court to Remove Teva Inhaler Patents From FDA Registry

Pharmaceutical company Teva Pharmaceuticals Industries Ltd. harmed competition by improperly listing asthma inhaler patents with the US Food and Drug Administration, the Federal Trade Commission argued in a brief urging a court to remove the listings.

The antitrust agency’s amicus brief, filed Friday, weighs in on a lawsuit brought by Teva over rival Amneal Pharmaceutical’s attempt to bring a generic version of asthma inhaler ProAir HFA to market. The FTC is siding with Amneal in arguing the court should remove Teva’s inhaler patents from the FDA’s Orange Book, a publication that lists drug products the FDA deems safe and effective. ...